Abstract |
The study of lysophosphatidic acid ( LPA) receptor has recently focused on its involvement in the pathogenesis of systemic sclerosis (SSc). We examined the inhibitory effects of the antagonist for the LPA receptor, a selective LPA1 and LPA3 antagonist ( Ki16425), on dermal and lung fibrosis in a mouse model of SSc. Ki16425 was administered intra-dermally after 6 h on the same sites as bleomycin injection. Histopathological examination showed that skin lesions were markedly attenuated by treatment with Ki16425 at doses of 1 and 10 mg/kg, along with reduced dermal thickness. Hydroxyproline contents in the Ki16425-treated skin showed a decrease of 35% (1 mg/kg) and 45% (10 mg/kg) compared with those in the oil-injected skin of the controls. The number of mast cells and phospho-Smad2/3-positive spindle cells of the Ki16425-treated skin was significantly decreased compared with that in the controls. Additionally, RT-PCR analysis showed that the mRNA levels of TGF-β1, CTGF, MIP-1α, IFN-γ and collagen α1(I) were significantly decreased in both the 1-mg/kg and 10-mg/kg groups of the Ki16425-treated mice compared with those in the controls. Furthermore, treatment with bleomycin and Ki16425 showed reduction in lung fibrosis, and the hydroxyproline contents in the lungs of the Ki16425-treated mice showed a decrease of 25% (1 mg/kg) and 32% (10 mg/kg) compared with those in the lungs of the controls. Taken together, Ki16425 was found to improve dermal and lung fibrosis in a mouse model of bleomycin-induced murine scleroderma. These results suggest that Ki16425 has the potential to be an effective new treatment for scleroderma.
|
Authors | Takenobu Ohashi, Toshiyuki Yamamoto |
Journal | Experimental dermatology
(Exp Dermatol)
Vol. 24
Issue 9
Pg. 698-702
(Sep 2015)
ISSN: 1600-0625 [Electronic] Denmark |
PMID | 25959255
(Publication Type: Journal Article)
|
Copyright | © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid
- CCN2 protein, mouse
- Ccl3 protein, mouse
- Chemokine CCL3
- Collagen Type I
- Isoxazoles
- Propionates
- RNA, Messenger
- Receptors, Lysophosphatidic Acid
- Smad2 Protein
- Smad2 protein, mouse
- Smad3 Protein
- Smad3 protein, mouse
- Transforming Growth Factor beta1
- Bleomycin
- Connective Tissue Growth Factor
- Interferon-gamma
- Hydroxyproline
|
Topics |
- Animals
- Bleomycin
- Cell Count
- Chemokine CCL3
(genetics)
- Collagen Type I
(genetics)
- Connective Tissue Growth Factor
(genetics)
- Disease Models, Animal
- Female
- Fibrosis
- Hydroxyproline
(metabolism)
- Interferon-gamma
(genetics)
- Isoxazoles
(administration & dosage, therapeutic use)
- Lung
(drug effects, metabolism, pathology)
- Mast Cells
- Mice
- Propionates
(administration & dosage, therapeutic use)
- RNA, Messenger
(metabolism)
- Receptors, Lysophosphatidic Acid
(antagonists & inhibitors)
- Scleroderma, Systemic
(chemically induced, drug therapy, metabolism, pathology)
- Skin
(drug effects, metabolism, pathology)
- Smad2 Protein
(metabolism)
- Smad3 Protein
(metabolism)
- Transforming Growth Factor beta1
(genetics)
|